Economic evaluation of diagnostic technologies supporting tailor-made decision in breast cancer treatment

• Project/Area Number: 25460610
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Medical sociology
• Research Institution: University of Tsukuba
• Principal Investigator: Kondo Masahide 筑波大学, 医学医療系, 准教授 (70334068)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Project Status: Completed (Fiscal Year 2015)
• Budget Amount: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000); Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: 乳がん / 個別化医療 / 診断技術 / 経済評価

Outline of Final Research Achievements

As an economic evaluation of tailor-made diagnostic technologies for breast cancer care, a cost-effectiveness study was conducted regarding an introduction of the 95-gene assay for the primary breast cancer into the benefit package of the National Health Insurance. The assay was targeted because it had been developed to the stage of diffusion in Japan. Changes of the treatment decision whether undergoing adjuvant chemotherapy or not according to validation case series for the development of the assay were applied for an economic Markov model of breast cancer care. An incremental cost-effectiveness ratio of including the assay into the benefit package was estimated at \4,754,269 in order to gain 1 quality adjusted life year. It was less than the threshold of social willingness-to-pay for new health care, \5,000,000, which suggested that making the assay available under the National Health Insurance was justifiable.

Research Products

• [Journal Article] Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study). (2014)
  • Author(s): Takada M, Ishiguro H, Nagai S, Ohtani S, Kawabata H, Yanagita Y, Hozumi Y, Shimizu C, Takao S, Sato N, Kosaka Y, Sagara Y, Iwata H, Ohno S, Kuroi K, Masuda N, Yamashiro H, Sugimoto M, Kondo M, Naito Y, Sasano H, Inamato T, Morita S, Toi M on behalf of the JBCRG-C03 Collaborative Group.
  • Journal Title: Breast Cancer Res Treat Volume: Volume 145, Issue 1 Issue: 1 Pages: 143-53
  • DOI: 10.1007/s10549-014-2907-9
  • NAID: 120005627665
  • Peer Reviewed
• [Journal Article] 医療経済－多遺伝子アッセイの経済評価例－ (2013)
  • Author(s): 近藤正英
  • Journal Title: 乳癌の臨床 Volume: 28 Pages: 365-373
• [Presentation] Predictive factors for pathologic complete response and disease-free survival after neoadjuvant chemotherapy with trastuzumab: A multicenter retrospective observational study in patients with HER2-positive primary breast cancer (JBCRG-C03 study) (2013)
  • Author(s): Takada M, Ishiguro H, Nagai S, Ohtani S, Kawabata H, Yanagita Y, Hozumi Y, Shimizu C, Takao S, Sato N, Kosaka Y, Sagara Y, Iwata H, Ohno S, Kuroi K, Masuda N, Yamashiro H, Sugimoto M, Kondo M, Naito Y, Sasano H, Inamoto T, Morita S, Toi M.
  • Organizer: The 2013 San Antonio Breast Cancer Symposium
  • Place of Presentation: San Antonio, TX, USA